Sonoma Pharmaceuticals (SNOA) Peer Comparison
$1.29
$0.00 (0.00%)As on 01-Sep-2026 16:00EDT
Market cap
$6 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Edit
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
6 | 14,975 | 12,310 | 11,972 | 10,425 |
Revenue ($ Mln) |
22 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
-2.26 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
-10.33 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
-45.16 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
-- | -- | 264.84 | -- | -- |
Price-To-Book |
0.97 | 123.68 | 17.91 | 1.79 | 129.60 |
Income Statement ($ Mln)
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
19.53 | 502.08 | 761.41 | 4,715.00 | 638.50 |
|
Cost of Revenue
|
12.11 | 28.27 | 12.98 | 2,665.00 | 47.48 |
|
Gross Profit
|
7.42 | 473.81 | 748.43 | 2,050.00 | 591.02 |
|
Operating Expenses
|
9.88 | 1,042.89 | 703.63 | 1,798.00 | 760.25 |
|
Operating Profit (EBIT)
|
-2.46 | -569.09 | 44.80 | 252.00 | -169.24 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-3.42 | -734.99 | 66.46 | -224.00 | -183.70 |
|
Provision for Tax
|
-0.24 | 0.56 | -33.19 | 8.00 | -0.53 |
|
Profit after Tax (Net Income)
|
-3.18 | -729.31 | 99.65 | -232.00 | -183.17 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
3.10 | -2,076.58 | 647.81 | 6,547.00 | 88.30 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
6.03 | 2,724.64 | 22.76 | 5,214.00 | 222.67 |
|
Current Liabilities
|
4.83 | 287.97 | 166.09 | 1,597.00 | 378.84 |
|
Total Liabilities
|
13.96 | 936.03 | 836.65 | 13,358.00 | 689.81 |
Assets ($ Mln)
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1.86 | 41.59 | 351.19 | 9,900.00 | 100.82 |
|
Current Assets
|
12.10 | 753.68 | 485.46 | 3,458.00 | 588.99 |
|
Total Assets
|
13.96 | 936.03 | 836.65 | 13,358.00 | 689.81 |
|
Total Debt*
|
0.84 | 2,728.72 | 6.11 | 4,017.00 | 241.30 |
|
Net Current Assets
|
7.27 | 509.78 | 319.38 | 1,861.00 | 210.15 |
Cashflow ($ Mln)
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-3.93 | -445.91 | 142.00 | 560.00 | -93.41 |
|
Cash Flow from Investing Activities
|
-0.19 | -24.49 | 69.76 | -279.00 | -0.48 |
|
Cash from Financing Activities
|
0.48 | 359.29 | -220.37 | -275.00 | 101.47 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-73.38 | -159.44 | 14.87 | -2.21 | -63.21 |
|
ROE (%)
|
-84.60 | 41.15 | 15.01 | -3.67 | -252.11 |
|
ROA (%)
|
-22.96 | -78.62 | 11.88 | -1.79 | -29.11 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-16.26 | -145.26 | 13.09 | -4.92 | -28.69 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.37 | 1.26 | 0.13 | 0.06 | 0.66 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
8.16 | -36.12 | -28.68 | -168.64 | 36.22 |
|
EPS Growth (%)
|
0.35 | -0.31 | -0.30 | -1.68 | 0.39 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.18 | -20.69 | 41.86 | -48.47 | -50.48 |
|
Price / Book Value
|
1.21 | -7.27 | 6.44 | 1.72 | 104.73 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.95 | -25.60 | 55.67 | 21.77 | -54.53 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.27 | -1.31 | 0.01 | 0.61 | 2.73 |
|
Short term debt to equity ratio
|
0.12 | -0.01 | 0.00 | 0.01 | 0.83 |
|
Current Ratio
|
2.50 | 2.62 | 2.92 | 2.17 | 1.55 |
|
Quick Ratio
|
1.75 | 2.52 | 2.85 | 1.08 | 1.48 |
|
Interest Coverage
|
-- | -12.84 | -- | -0.02 | -27.02 |
Operating Efficiency Ratios
| Sonoma Pharmaceuticals (SNOA) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
27.83 | 27.77 | 7.85 | 19.94 | 35.16 |
|
Asset Turnover
|
1.41 | 0.54 | 0.91 | 0.36 | 1.01 |
|
Receivable days
|
86.01 | 52.44 | 28.27 | 70.73 | 104.82 |
|
Inventory Days
|
98.99 | 172.81 | 355.76 | 226.89 | 167.98 |
|
Payable days
|
43.36 | 296.14 | 785.55 | 45.50 | 529.03 |
|
Cash Conversion Cycle
|
141.64 | -70.89 | -401.52 | 252.12 | -256.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
